

Serial no. 09/911,703

Attorney Docket no. 27693-01008

**RECEIVED  
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE CENTRAL FAX CENTER**

JAN 20 2006

Serial No.:	09/911,703
Confirmation No.:	4927
Filed:	25 July 2001
Applicant:	Darrell R. ANDERSON et al.
For:	Anti-CD20 Antibodies

Group Art Unit:	1644
Examiner:	R. Schwadron

Mail Stop Amendment  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

**POWER OF ATTORNEY BY ASSIGNEE AND CHANGE OF CORRESPONDENCE ADDRESS**

The assignee of the entire right, title, and interest in U.S. patent application serial no. 09/911,703, Biogen Idec Inc., hereby revokes all previous powers of attorney in the above-identified application and appoints the practitioners associated with

**CUSTOMER NUMBER 47553**

as its attorneys and agents to prosecute the captioned patent application, and to transact all business in the U.S. Patent and Trademark Office connected therewith.

Direct all correspondence regarding this application to the address associated with **CUSTOMER NUMBER 47553**.

Please note the new attorney docket number for this application, **27693-01008**.

This application is a continuation of application serial no. 08/475,813, filed 07 June 1995, now U.S. Patent No. 6,682,734; which is a divisional of application serial no. 08/149,099, now U.S. Patent No. 5,736,137. Assignments of the '137 patent have effect as to this application. M.P.E.P. § 306.

Pursuant to 37 C.F.R. § 3.73(b), the undersigned states that Biogen Idec Inc. is the assignee of the entire right, title, and interest in the captioned application by virtue of the following assignments for U.S. Patent No. 5,736,137 recorded in the Patent and Trademark Office:

BI 0029 CP1C2

Serial no. 09/911,703

Attorney Docket no. 27693-01008

From the inventors recorded at Reel 006850,  
to IDEC Pharmaceuticals Corp., Frame 0468;

From IDEC Pharmaceuticals Corp. recorded at Reel 007171,  
to Merrill Lynch/Morgan Stanley Associates, L.P., Frame 0587;

From Merrill Lynch/Morgan Stanley Associates, L.P. recorded at Reel 007934,  
to IDEC Pharmaceuticals Corp., Frame 0284.

The following documents regarding the '137 patent are also recorded in the Office:


From IDEC Pharmaceuticals Corp. recorded at Reel 007279,  
in favor of Silicon Valley Bank as collateral agent Frame 0680;  
for Venture Lending & Leasing, Inc.,  
granting a security interest,

From Venture Lending & Leasing, Inc. recorded at Reel 010340,  
in favor of IDEC Pharmaceuticals Corp., Frame 0869.  
releasing all security interests,

Biogen Idec Inc. is the successor in interest to IDEC Pharmaceuticals Corp.

The undersigned, whose title is supplied below, is authorized to act on behalf of the assignee.

Respectfully submitted,

  
Date

Christopher A. Dayton  
Associate General Counsel, IP  
Biogen Idec Inc.

BI 0029 CP1C2